The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Methylprednisolone Pulse Treatment of Graves’ Ophthalmopathy Is Not Associated with Secondary Adrenocortical Insufficiency
Open accessAbstract
OBJECTIVE: Graves' ophthalmopathy (GO) is an inflammatory disease in the orbital region. The first-line medical treatment is glucocorticoids. An important potential side effect of glucocorticoid treatment is suppression of the hypothalamic-pituitary-adrenal (HPA) axis with impairment of endogenous cortisol production, implicating symptoms of adrenocortical insufficiency, especially in the period after cessation of therapy with possible risks in cases of intercurrent illness. The aim of this study was to evaluate HPA axis function before and after methylprednisolone pulse treatment of GO. STUDY DESIGN: HPA axis function was evaluated by measurements of plasma ACTH and an ACTH stimulation test with plasma cortisol measurements at 0 and 30 min after an intravenous bolus of synthetic ACTH (Synacthen® 250 µg). This was done in 12 patients with GO before and at cessation of methylprednisolone pulse treatment (500 mg i.v. per week for 6 weeks followed by 250 mg i.v. per week for an additional 6 weeks). RESULTS: All patients included fulfilled the criteria of intact HPA axis function before and at cessation of methylprednisolone pulse treatment. Data are given as medians (with ranges). Before glucocorticoid treatment basal plasma cortisol was 290 nM (196-579) and 786 nM (612-1,050) after ACTH stimulation. At cessation of therapy the corresponding values were 309 nM (88-718) and 852 nM (524-1,011), respectively. Thus, all patients passed a 30-min stimulated plasma cortisol of 500 nM. Before treatment plasma ACTH was 4.2 pmol/l (4-16) and at cessation of therapy the corresponding value was 4.8 pmol/l (2-9; p = 0.27). CONCLUSION: Transient suppression of the HPA axis with secondary adrenocortical insufficiency does not seem to be a common phenomenon after intravenous methylprednisolone pulse therapy for GO. Therefore, routine precautions are not necessary. However, our results do not exclude that transient secondary adrenocortical insufficiency might occur occasionally.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent studies have shown that the treatment with an IV methylprednisolone administered every week protocol (cumulative dose of 4.5 g) does not cause GC-induced AI [24,25,26,27].”
From Glucocorticoid withdrawal-an overview on when and how to diagnose adrenal insufficiency in clinical practice (2021) · cites this paper as [26]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy
Mourits, M. P., Prummel, M. F., Wiersinga, W. M., & Koornneef, L. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.2331047.x · Cited by 1,001
Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO
Bartalena, L., Baldeschi, L., Dickinson, A., Eckstein, A., Kendall-Taylor, P., Marcocci, C., Mourits, M., Perros, P., Boboridis, K., Boschi, A., et al. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0666 · Cited by 795
Corticotropin tests for hypothalamic-pituitary- adrenal insufficiency: a metaanalysis
Kazlauskaite, R., Evans, A. T., Villabona, C. V., Abdu, T. A. M., Ambrosi, B., Atkinson, A. B., Choi, C. H., Clayton, R. N., Courtney, C. H., Gonc, E. N., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0710 · Cited by 385
Schlaghecke, R., Kornely, E., Santen, R. T., & Ridderskamp, P. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201233260403 · Cited by 381
Diagnosis of Adrenal Insufficiency
Dorin, R. I., Qualls, C. R., & Crapo, L. M. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-3-200308050-00009 · Cited by 374
Bartalena, L., Krassas, G. E., Wiersinga, W., Marcocci, C., Salvi, M., Daumerie, C., Bournaud, C., Stahl, M., Sassi, L., Veronesi, G., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2389 · Cited by 370
Marcocci, C. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.8.3562 · Cited by 309
Huizenga, N. A. T. M. (1998) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.1.144 · Cited by 265
LaRochelle, G. E., LaRochelle, A. G., Ratner, R. E., & Borenstein, D. G. (1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90277-v · Cited by 165
Why glucocorticoid withdrawal may sometimes be as dangerous as the treatment itself
Dinsen, S., Baslund, B., Klose, M., Rasmussen, A. K., Friis-Hansen, L., Hilsted, L., & Feldt-Rasmussen, U. (2013) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2013.05.014 · Cited by 148
Cited by
Bartalena, L., Kahaly, G. J., Baldeschi, L., Dayan, C. M., Eckstein, A., Marcocci, C., Marinò, M., Vaidya, B., Wiersinga, W. M., _, _., et al. (2021) · European Journal of Endocrinology · doi:10.1530/eje-21-0479 · Cited by 1,054
Management of Graves Thyroidal and Extrathyroidal Disease: An Update
Kahaly, G. J. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa646 · Cited by 223
Glucocorticoid induced adrenal insufficiency
Prete, A., & Bancos, I. (2021) · BMJ · doi:10.1136/bmj.n1380 · Cited by 155
Kumar, R., & Wassif, W. (2022) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2021-207895 · Cited by 69
Glucocorticoids in Graves’ orbitopathy: mechanisms of action and clinical application
Längericht, J., Kramer, I. F., & Kahaly, G. J. (2020) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820958335 · Cited by 61
Metadata
- Authors
- Jespersen, S., Nygaard, B., & Kristensen, L. Ø.
- Affiliations
- Herlev Hospital (DK)
- Corresponding author
- Nygaard, Birte
- Venue
- European Thyroid Journal
- Publisher
- Bioscientifica
- Published
- 2015-10-27
- Volume
- 4
- Issue
- 4
- Pages
- 222-225
- ISSN
- 2235-0640 (ISSN-L)
- 2235-0802
- PMC
- PMC4716422
- OpenAlex
- W2227985276
- Cited by
- 22
- References
- 26
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 6 · 2023: 1 · 2022: 2 · 2021: 4 · 2020: 5 · 2017: 1
- FWCI
- 0.26
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- European Thyroid Journal (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Ophthalmology and Eye Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Keywords
- Graves' ophthalmopathy, methylprednisolone pulse therapy, hypothalamic-pituitary-adrenal axis suppression, glucocorticoid adverse effects, ACTH stimulation test, plasma cortisol, ACTH
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.